Skip to main content
Vetoquinol SA logo

Vetoquinol SA — Investor Relations & Filings

Ticker · VETO ISIN · FR0004186856 LEI · 969500YP0AETQIK48R39 PA Manufacturing
Open in API
Filings indexed 299 across all filing types
Latest filing 2014-01-16 Capital/Financing Update
Country FR France
Listing PA VETO

About Vetoquinol SA

https://www.vetoquinol.com/en

Vetoquinol SA is a global animal health company that researches, develops, produces, and markets veterinary medicines and non-medicinal products. The company provides solutions for both companion animals (cats and dogs) and livestock (cattle and pigs). Its product portfolio addresses a wide range of therapeutic areas, including mobility, dermatology, anti-parasitics, antibiotics, internal medicine, and behavior management. Founded in 1933, the independent, family-owned business focuses on innovation and maintaining a close relationship with veterinary professionals to support animal well-being.

Recent filings

Filing Released Lang Actions
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DES MOYENS ALLOUES AU CONTRAT DE LIQUIDITE" (Semi-annual Balance Sheet of Means Allocated to the Liquidity Contract) and is dated "Au 31 décembre 2013". This clearly indicates a periodic financial report covering a six-month period (semestriel). This aligns perfectly with the definition of an Interim / Quarterly Report (IR), which covers periods shorter than a year. Although it relates to a liquidity contract, the core content is a periodic financial statement update, making IR the most appropriate classification over a general regulatory filing (RNS) or a specific financing update (CAP). The document is short and contains the actual data, not just an announcement of a report.
2014-01-16 French
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 98% confidence The document is a press release dated January 7, 2014, announcing the appointment of Jean-Yves Ravinet as the Group Chief Operating Officer (COO). This type of announcement concerns a change in senior management personnel. Based on the provided definitions, the category 'Board/Management Information' (Code: MANG) is the most appropriate classification for announcements regarding changes in senior management.
2014-01-07 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 99% confidence The document is a press release dated January 7, 2014, announcing the appointment of Jean-Yves Ravinet as Deputy CEO ('Directeur général délégué Groupe'). This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). The document is short and structured like a formal corporate announcement, not a comprehensive report (like 10-K or IR).
2014-01-07 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 95% confidence The document announces specific business developments: the launch of new product lines (Flexadin Plus/Advanced) and the expansion of an existing product (Zylkène®) into the US market. It details product features, market context, and includes quotes from the CEO. This content is characteristic of a press release or a specific business update rather than a comprehensive statutory filing (like 10-K or IR) or a formal shareholder communication (like DEF 14A or AGM-R). Since it is a specific business announcement that doesn't fit the other specialized categories (like M&A, Capital Change, or Dividend), it falls best under the general 'Regulatory Filings' (RNS) category, which often serves as a catch-all for press releases announcing operational news, or potentially an 'Investor Presentation' (IP) if it were structured as slides, but given the format, RNS is the most appropriate fit for a general operational news release.
2013-12-16 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is a press release dated December 16, 2013, announcing product launches (Flexadin Plus, Flexadin Advanced, and Zylkène in the US) by the company Vétoquinol. It details product features, market strategy, and includes boilerplate information about the company and investor/press contacts. This type of announcement, focusing on operational updates, product news, and strategic direction, is typically classified as a general corporate announcement or press release. Since there is no specific category for a general product launch press release, and it is not a formal regulatory filing like a 10-K, an Earnings Release (ER), or a specific financial report (IR, AR), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous official announcements that don't fit elsewhere. It is not an Earnings Release (ER) as it focuses on product launches, not financial results. It is not an Investor Presentation (IP) as it is a text-based press release, not a slide deck. It is not a Report Publication Announcement (RPA) because it is the substantive news itself, not just an announcement that a report is available.
2013-12-16 French
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 98% confidence The document is a press release dated October 24, 2013, detailing the company's revenue ('Chiffre d'affaires') for the third quarter (T3) of 2013 and the cumulative first nine months. It presents key financial figures, growth rates, and business segment performance. This format, focusing on the immediate release of periodic financial results (quarterly revenue highlights), aligns perfectly with the definition of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR), nor is it a transcript or a formal regulatory filing announcement (RPA/RNS), but the actual summary of the results. Q3 2013
2013-10-24 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.